1. Metformin’s dual impact on Gut microbiota and cardiovascular health: A comprehensive analysis
- Author
-
Turky Omar Asar, Fahad A. Al-Abbasi, Ryan Adnan Sheikh, Mustafa Adnan Mustafa Zeyadi, Muhammad Shahid Nadeem, Salma Naqvi, Vikas Kumar, and Firoz Anwar
- Subjects
Metformin ,Gut Microbiota ,CVD ,Firmicutes ,Proteobacteria ,Parabacteroides ,Therapeutics. Pharmacology ,RM1-950 - Abstract
Cardiovascular diseases (CVD) cause significant global morbidity, mortality and public health burden annually. CVD alters richness, diversity, and composition of Gut microbiota along with RAS and histopathological differences. Present study explores Metformin role in mitigating doxorubicin induced cardiovascular toxicity/remodeling. Animals were divided into 4 groups with n=6: Group I (N. Control) free access to diet and water; Group II (MET. Control) on oral Metformin (250 mg/kg) daily; Group III (DOX. Control) alternate day intraperitoneal Doxorubicin (3 mg/kg) totaling 18 mg/kg; Group IV (DOX. MET. Control) received both daily oral Metformin (250 mg/kg) and alternate day Doxorubicin (3 mg/kg). Gut microbial analysis was made from stool before animals were sacrificed for biochemical and histopathological analysis. Significant alterations were observed in ɑ and β-diversity with new genus from Firmicutes, specifically Clostridia_UCG-014, Eubacterium ruminantium, and Tunicibacter, were prevalent in both the DOX. Control and DOX.MET groups. Proteobacteria, represented by Succinivibrio, were absent in all groups. Additionally, Parabacteroides from the Bacteroidia phylum was absent in all groups except the N. control. In the DOX.MET Control group, levels of Angiotensin II ( 7.75± 0.49 nmol/min, p
- Published
- 2024
- Full Text
- View/download PDF